{
  "kind": "treatment",
  "slug": "loxapine-inhalation-adasuve",
  "type": "antipsychotic",
  "name": "Loxapine Inhalation (Adasuve)",
  "summary": "An inhaled typical antipsychotic formulation used for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.",
  "description": "Loxapine inhalation powder (Adasuve) is a typical antipsychotic delivered via a single-use, breath-actuated inhaler. It is indicated for the rapid control of mild-to-moderate agitation in adults with schizophrenia or bipolar I disorder. The inhaled route provides quick onset while minimizing systemic exposure compared to oral or parenteral formulations. Adasuve carries a boxed warning for bronchospasm and is available only through a REMS program.",
  "category": "medications/antipsychotics",
  "tags": [
    "loxapine",
    "typical-antipsychotic",
    "inhalation",
    "acute-agitation"
  ],
  "metadata": {
    "drug_classes": [
      "Typical Antipsychotic"
    ],
    "therapeutic_categories": [
      "Psychosis",
      "Bipolar Disorder",
      "Agitation"
    ],
    "mechanism_categories": [
      "Dopamine Blocker",
      "Other"
    ],
    "administration_routes": [
      "Inhaled"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Adasuve"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Acute"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Emergency Medicine"
    ],
    "fda_approval_year": 2012
  },
  "clinical_metadata": {
    "primary_indications": [
      "Psychosis",
      "Bipolar"
    ],
    "off_label_uses": [],
    "contraindications": [
      "History of asthma or COPD",
      "Active airway disease",
      "Current respiratory symptoms",
      "Known hypersensitivity to loxapine or amoxapine"
    ],
    "monitoring_required": [
      "Respiratory status for at least 1 hour post-dose",
      "Signs of bronchospasm"
    ],
    "efficacy_rating": {
      "agitation-control": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "loxapine inhalation",
      "adasuve",
      "inhaled antipsychotic",
      "acute agitation"
    ],
    "synonyms": [
      "loxapine inhaled powder"
    ],
    "common_misspellings": [
      "adasuv",
      "loxapin"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Rapid control of mild-to-moderate agitation in adults with schizophrenia",
        "Rapid control of mild-to-moderate agitation in adults with bipolar I disorder"
      ]
    },
    {
      "type": "mechanism",
      "text": "Loxapine is a dibenzoxazepine antipsychotic that antagonizes central dopamine D2 and serotonin 5-HT2A receptors. The inhalation form provides rapid delivery to the systemic circulation via the lungs."
    },
    {
      "type": "dosing",
      "adult": {
        "agitation": "10 mg inhalation once; a second dose may be given after 2 hours if needed (maximum 20 mg in 24 hours)"
      },
      "geriatric": "Use with caution; no specific adjustment but increased monitoring for sedation and hypotension",
      "hepatic_impairment": "Use with caution",
      "renal_impairment": "No adjustment required"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Single-use inhaler delivering 10 mg loxapine powder"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within 10 minutes; duration approximately 2â€“4 hours."
    },
    {
      "type": "adverse_effects",
      "common": [
        "dysgeusia (bad taste)",
        "throat irritation",
        "sedation"
      ],
      "less_common": [
        "hypotension",
        "extrapyramidal symptoms"
      ],
      "serious": [
        "bronchospasm",
        "respiratory distress",
        "neuroleptic malignant syndrome"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Warning: Bronchospasm. Adasuve can cause bronchospasm that has the potential to lead to respiratory distress and arrest. Only available through the Adasuve REMS Program.",
      "other": [
        "Monitor respiratory status for at least 1 hour post-dose",
        "Avoid in patients with current or history of airway disease"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "CNS depressants",
          "risk": "Enhanced sedation",
          "action": "Use caution"
        },
        {
          "with": "Antihypertensives",
          "risk": "Additive hypotensive effect",
          "action": "Monitor blood pressure"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Respiratory rate and oxygen saturation",
        "Signs and symptoms of bronchospasm",
        "Level of sedation"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use if benefits outweigh risks",
      "lactation": "Unknown excretion in human milk; caution advised",
      "pediatrics": "Not approved",
      "geriatrics": "Greater risk of sedation and orthostatic hypotension"
    },
    {
      "type": "tapering",
      "text": "Not applicable for single-use acute treatment."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Requires healthcare setting equipped to manage acute bronchospasm",
        "Provides faster onset than oral loxapine but shorter duration",
        "Intended for patients who can cooperate with inhalation"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Adasuve Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "FDA REMS Program Information",
          "url": "https://www.accessdata.fda.gov/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Loxapine Inhalation (Adasuve): Rapid Agitation Control",
    "description": "Adasuve is an inhaled form of loxapine for rapid treatment of agitation in schizophrenia and bipolar I disorder. Learn about dosing, safety, and REMS requirements."
  }
}
